Is Zepbound Safe During Pregnancy? Understanding the Risks and Considerations

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide and other GLP-1 receptor agonists are powerful tools for weight management, but pregnancy safety remains a critical consideration. Current evidence suggests these medications should be discontinued before attempting conception, though individual medical circumstances vary significantly.

What the FDA Says About GLP-1 Drugs and Pregnancy

The FDA is not recommended during pregnancy. This classification means the medication's safety profile in pregnant people has not been definitively established through controlled clinical trials. Zepbound (semaglutide) carries similar pregnancy concerns, with manufacturers recommending discontinuation before conception.

Current prescribing guidance advises patients of childbearing age to avoid pregnancy while using GLP-1 medications. The lack of human pregnancy data creates uncertainty about potential risks to fetal development, organ formation, and long-term outcomes. Healthcare providers typically recommend switching to alternative weight management strategies if pregnancy is planned or occurs during treatment.

Animal Study Findings on GLP-1 Receptor Agonists During Pregnancy

Preclinical animal studies evaluating tirzepatide have demonstrated fetal developmental concerns at doses relevant to human therapeutic use. These findings include effects on fetal growth and skeletal development in rodent models, which prompted the conservative FDA pregnancy classification. While animal models do not always predict human outcomes, this evidence supports the current recommendation to discontinue treatment before pregnancy.

Semaglutide studies in pregnant animals also showed dose-dependent developmental effects, leading pharmaceutical manufacturers to advise against use during pregnancy. The consistent pattern across GLP-1 compounds suggests a class effect that warrants caution. Until robust human pregnancy data becomes available through prospective studies, extrapolation from animal models remains the primary safety evidence.

Planning Pregnancy While Managing Your Weight

If you are considering pregnancy, discussing your weight management plan with both your reproductive health provider and prescribing clinician is essential. Many patients benefit from establishing sustainable lifestyle changes before stopping GLP-1 treatment, including structured nutrition and movement habits. PlexusDx providers can help create a transition plan that maintains progress while prioritizing reproductive safety.

Some patients choose to pause GLP-1 therapy 2-3 months before attempting conception, allowing the medications to clear from their system completely. This timing provides a buffer period and allows your body to stabilize on alternative management strategies. Combining evidence-based behavioral approaches with medical supervision during this transition optimizes both weight outcomes and pregnancy readiness.

What if You Become Pregnant While Taking Tirzepatide or Semaglutide?

Accidental pregnancy while using GLP-1 medications requires immediate consultation with your obstetric care team and prescribing provider. Most medical guidelines recommend discontinuing the medication as soon as pregnancy is confirmed, though individual risk-benefit assessment is necessary. Early prenatal counseling can help assess any potential exposure effects and establish appropriate monitoring throughout pregnancy.

The decision to discontinue should involve collaborative discussion between your obstetrician, internist, and family planning preferences. Some patients choose enhanced fetal monitoring or specialist consultation to evaluate any potential developmental concerns. Documentation of medication exposure timing and amounts helps your healthcare team provide personalized guidance about pregnancy management and outcomes monitoring.

Personalized Weight Management: Before, During, and After Pregnancy

PlexusDx Precision Peptide Genetic Test identifies your unique peptide pathway genetics, helping tailor weight management strategies across all life stages. Understanding genetic variants in GIPR and FTO, and MC4R pathways enables personalized approaches that work with your biology rather than against it. This genetic insight remains valuable whether you are using GLP-1 medications, planning pregnancy, or managing weight postpartum.

Postpartum weight management often requires different therapeutic approaches than preconception treatment, especially if breastfeeding is planned. PlexusDx providers can reassess your genetic predispositions and clinical response once pregnancy and lactation are complete, helping restart GLP-1 therapy safely if appropriate. Your genetic profile continues to inform optimal medication choice and dosing strategy throughout your reproductive years.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is it safe to take tirzepatide if I might become pregnant?

No. Tirzepatide carries pregnancy risks based on animal studies and lacks human pregnancy data. PlexusDx recommends discontinuing the medication before attempting conception and discussing alternative weight management strategies with your healthcare team. Contact your PlexusDx provider immediately if pregnancy occurs during treatment.

How long should I wait after stopping GLP-1 medication before trying to conceive?

Most providers recommend waiting 2-3 months after discontinuing tirzepatide or semaglutide to allow complete clearance and physiologic stabilization. This timing varies based on individual factors including prior medication duration, metabolic status, and fertility assessment. Discuss specific timing recommendations with both your reproductive endocrinologist and PlexusDx clinician.

Can I use PlexusDx compounded tirzepatide while breastfeeding?

Current evidence is limited regarding GLP-1 passage into breast milk and potential infant effects. Most providers recommend caution and dose evaluation before resuming these medications postpartum if breastfeeding. Your PlexusDx provider can review individual circumstances and help determine safe timing for medication restart during lactation.

What weight management options exist during pregnancy if I was using GLP-1 therapy?

Pregnancy-safe weight management focuses on structured nutrition, safe movement, behavioral support, and stress management without GLP-1 medications. Many patients successfully maintain health through these evidence-based approaches. Discuss specific strategies with your obstetrician and consider revisiting GLP-1 options postpartum after metabolic stabilization.

Does PlexusDx Precision Peptide Genetic Test help with pregnancy planning decisions?

Yes. Your genetic variants in GIPR and FTO, and MC4R pathways inform personalized weight management across all life stages, including preconception planning. Understanding your peptide pathway genetics helps your PlexusDx provider design optimal strategies whether pausing medications for pregnancy or managing weight postpartum. This genetic insight remains valuable beyond any individual treatment phase.

Related Reading

• What Genetic Factors Affect Ptsd Severity How Can Understanding Help Manage Risks
• Fridays Zepbound
• Hims Zepbound
• Form Health Zepbound

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.